Tracers / [18F]FE-PE2I
[18F]FE-PE2I
Also written as [18F]FE-PE2I; [F-18]FE-PE2I; FE-PE2I
- Radionuclide
- F-18 t½ 109.77 min
- Modality
- PET
- Production route
- —
- Stage
- —
- Syntheses indexed
- 5
What it is
- Compound class
- Cocaine derivative / tropane-based dopamine transporter (DAT) ligand
- Target / mechanism
- Dopamine transporter (DAT) PMID 38696063
- Clinical application
- PET imaging of dopamine transporter density for diagnosis of Parkinson's disease PMID 34206688
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| ScanSys synthesizer Scansys Laboratorieteknik | fixed tubing | HPLC | 7.6 ± 3.6% | — | OTsE-PE2I (tosylethyl-PE2I) PharmaSynth AS, Tartu, Estonia | 34206688 2021 Pharmaceuticals (Basel) an automated radiochemistry system (Scansys Laboratorieteknik ApS) with a preparative Onyx C18 high-performance liquid chromatography (HPLC) system — reasonable RCYs of 7.6 ± 3.6% (n = 73, starting from ca. 45 GBq as the standard) were achieved |
| ScanSys synthesizer Scansys Laboratorieteknik | fixed tubing | HPLC | 10.8 ± 3.7% | — | OTsE-PE2I (tosylethyl-PE2I) PharmaSynth AS, Tartu, Estonia | 34206688 2021 Pharmaceuticals (Basel) Applying the improved preparative HPLC conditions with the ascorbate buffer improved the RCYs slightly (10.8 ± 3.7%, n = 161). — Applying the improved preparative HPLC conditions with the ascorbate buffer improved the RCYs slightly (10.8 ± 3.7%, n = 161). |
| Synthera+ IBA | vendor cassette | HPLC | 16.9 ± 2.7% | — | OTsE-PE2I / TsOE-PE2I PharmaSynth AS, Tartu, Estonia | 34206688 2021 Pharmaceuticals (Basel) the production of [18F]FE-PE2I was transferred to a cassette-based system using a Synthera®+ HPLC (IBA). — The process was fully validated with starting activities up to 140 GBq giving an average RCY of 16.9 ± 2.7% (n = 3). |
| Synthera+ IBA | vendor cassette | HPLC | 33 ± 2% | — | OTsE-PE2I / TsOE-PE2I PharmaSynth AS, Tartu, Estonia | 34206688 2021 Pharmaceuticals (Basel) The synthesis was implemented on the Synthera®+ module — Using DMSO as the reaction solvent generated the product with the RCY of 33 ± 2% (n = 3) from the 45-GBq starting activity (Figure 8). |
| TRACERlab FX2 N GE HealthCare | custom manifold | HPLC+SPE | 39 ± 8% yes | >95% | tosylethyl-PE2I PharmaSynth AS, Tartu, Estonia | 38696063 2024 EJNMMI Radiopharm Chem GE TRACERLab FX2 N — [18F]FE-PE2I was produced with a radiochemical yield of 39 ± 8% (n = 4, relative [18F]F− delivered to the module) |
Need this precursor?We can point you to suppliers for [18F]FE-PE2I, or handle the enquiry for you.
Get in touchQuality control Preliminary — inferred from compound class
- Ph. Eur. monograph
- —
- USP monograph
- —
How this set was arrived at. base set per Ph. Eur. general monograph 0125 (rule); organic-phase radiosynthesis assumed from isotope/compound class, no synthesis data confirming it -> GC residual solvents (preliminary); conventional nucleophilic 18F-fluorination assumed from isotope/compound class, no synthesis data confirming K222 use -> Kryptofix test (preliminary)
Tests listed by reference only. Monograph texts are copyrighted and are not reproduced here. How these are derived
Setting up quality control?We can help you scope the equipment needed to release [18F]FE-PE2I.
Get in touchNotes
Added from reverse module search (stage 6); 2 article(s) with F-18.